Ekso Bionics Delays Reverse Stock Split Effective Date to June 2, 2025

Exoskeleton developer Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) has pushed back the implementation date for its planned reverse stock split, rescheduling the corporate action from May 27, 2025 to June 2, 2025 at 12:01 a.m. Pacific time. Trading of the company’s shares will resume on The Nasdaq Capital Market under the same ticker symbol “EKSO” but with adjusted share counts reflecting the 1-for-15 split ratio.

Background on the Stock Split Initiative

The reverse split, which was greenlit by Ekso Bionics shareholders at a special meeting on May 16, 2025, fundamentally restructures the company’s capital structure. The corporate action will consolidate approximately 35.5 million pre-split shares of common stock into roughly 2.4 million post-split shares, with no corresponding change to par value per share. A new CUSIP identifier (282644 400) will accompany the effective reverse split.

Why the Timing Adjustment Matters

The postponement stems from Ekso Bionics’ ongoing effort to restore compliance with Nasdaq listing standards. In December 2024, the exchange notified the company that its common stock had failed to meet the minimum bid price requirement under Nasdaq Capital Market rules. To regain and maintain listing status, Ekso Bionics must achieve a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days—a threshold the reverse split is designed to facilitate by mechanically raising the per-share trading price.

Mechanics of the Reverse Split

Shareholders holding electronic book-entry shares through brokerage accounts or 401(k) plans will see automatic adjustments made by their custodian institutions—no action required. Those holding physical share certificates can contact VStock Transfer, LLC, the company’s designated transfer agent, to exchange certificated shares for new ones reflecting the post-split adjustment.

Fractional shares resulting from the reverse split will be rounded up to whole shares, eliminating the need for cash payments in lieu. The company’s stock options, warrants, and restricted stock units will undergo corresponding adjustments in share count and exercise prices to maintain proportional economic value.

Impact on Ownership and Capital Structure

The reverse split will not alter the total number of authorized common shares or significantly change any individual stockholder’s percentage ownership stake in Ekso Bionics. All shareholders are affected uniformly by the capital restructuring. The company’s authorized share count remains unchanged, meaning the reverse split operates as a technical recapitalization without fundamental shifts in governance rights or equity distribution.

About Ekso Bionics

Based in the San Francisco Bay Area, Ekso Bionics is a leading developer of exoskeleton technologies that enhance human performance across medical and industrial settings. The company’s portfolio addresses applications ranging from rehabilitation and mobility assistance for individuals with paralysis to strength augmentation for workers in demanding job environments. Listed on The Nasdaq Capital Market under the symbol EKSO, the company continues advancing robotics solutions designed to restore, amplify, and enhance human function.